Journal: Scientific Reports

Article Title: Drug repurposing of pyrimidine analogs as potent antiviral compounds against human enterovirus A71 infection with potential clinical applications

doi: 10.1038/s41598-020-65152-4

Figure Lengend Snippet: In vivo evaluation of gemcitabine, sofosbuvir, and LY2334737. 6-day-old BALB/c mice were infected with EV-A71 at a dose of 2 × 10 7 PFU per mouse via intraperitoneal injection (i.p.). At 1 hpi, the EV-A71-infected mice were treated with first dose of drug. The dose of drug used was: 0.25 mg/kg for gemcitabine, 2 mg/kg for sofosbuvir and 0.32 mg/kg for LY2334737 (equimolar to 0.25 mg/kg gemcitabine). PBS was used as treatment control. The survival ( a and c ) and clinical scores ( b and d ) of the mice were recorded using the mice clinical scoring system for up to 14 dpi.

Article Snippet: LY2334737 (MedChem Express, #HY-13672) was given to 6–day-old suckling BALB/c mice by oral feeding with dose of 0.32 mg/kg per mouse.

Techniques: In Vivo, Infection, Injection, Control

Journal: Scientific Reports

Article Title: Drug repurposing of pyrimidine analogs as potent antiviral compounds against human enterovirus A71 infection with potential clinical applications

doi: 10.1038/s41598-020-65152-4

Figure Lengend Snippet: Viral load inhibition by LY2334737 and sofosbuvir on suckling BALB/c mice. ( a ) 6–day-old BALB/c mice were administered with 0.32 mg/kg LY2334737 or 2 mg/kg sofosbuvir at 0.32 mg/kg and the bodyweight of drug-treated mice was measured daily for 15 days. All mice survived treatment cytotoxicity challenge. Data in this figure is represented as mean±standard deviation. Viral load inhibition by sofosbuvir and LY2334737 in muscle tissue of EV-A71-infected mice were determined using plaque assay ( b ), H&E ( c–f ) and IHC ( g–j ). 6-day-old BALB/c mice were infected with EV-A71 at 2×10 7 PFU per mouse via i.p. At 1 hpi, the EV-A71-infected mice were treated with first dose of drug. The dose of drug used was: 2 mg/kg for sofosbuvir and 0.32 mg/kg for LY2334737. PBS was used as treatment control. ( b ) A slight decrease in viral titer was observed in sofosbuvir treated mice compared to PBS control. Data in this figure was presented as mean and individual values. ( c–f ) H&E staining showed no obvious muscle necrosis in sofosbuvir-treated mice ( d ) and mild necrosis in LY2334737-treated mice ( f ), whilst PBS control showed extensive necrosis ( c,e ). ( g–j ) IHC staining muscle tissue showed extensive antigen positive in PBS control animals ( g,i ) while similar viral antigen distribution was observed in LY2334737 treated animals ( j ). However, low viral antigen is present in sofosbuvir treated animals ( h ). Data displayed are representative images of each group (n = 6). Magnification for H&E and IHC staining 20×.

Article Snippet: LY2334737 (MedChem Express, #HY-13672) was given to 6–day-old suckling BALB/c mice by oral feeding with dose of 0.32 mg/kg per mouse.

Techniques: Inhibition, Standard Deviation, Infection, Plaque Assay, Control, Staining, Immunohistochemistry